Search
for
Sort by
Research 421–450 of 1000+
- Alopecia Areata Increases the Risk of Stroke: a 3-year Follow-Up Study
- Physiopathological role of the enzymatic complex 5α-reductase and 3α/β-hydroxysteroid oxidoreductase in the generation of progesterone and testosterone neuroactive metabolites
- Efficacy and safety of bimatoprost 0.03% versus minoxidil 3% in enhancement of eyebrows: A randomized, double‐blind, split‐face comparative study
- The expression of the gene <i>asebia</i> in the laboratory mouse: 3. Sebaceous glands
- Nongenomic effects of 1α,25-dihydroxyvitamin D 3 on cartilage formation deduced from comparisons between Cyp27b1 and Vdr knockout mice
- Erratum to: Evaluation of the Effect of NT-3 and Biodegradable Poly-L-lactic Acid Nanofiber Scaffolds on Differentiation of Rat Hair Follicle Stem Cells into Neural Cells In Vitro
- Low-dose oral minoxidil for treating alopecia: A 3-year North American retrospective case series
- Serine Biosynthesis In Human Hair Follicles By The Phosphorylated Pathway: Follicular 3-Phosphoglycerate Dehydrogenase
- Evaluation of oxidative stress, 3-Nitrotyrosine, and HMGB-1 levels in patients with wet type Age-Related Macular Degeneration
- Glioblastoma cells express crucial enzymes involved in androgen synthesis: 3β‐hydroxysteroid dehydrogenase, 17‐20α‐hydroxylase, 17β‐hydroxysteroid dehydrogenase and 5α‐reductase
- Studies on microscopic identification of animal drugs’ remnant hair (3): identification of several species of Cauda Cervi
- Relation between treatment efficacy and cumulative dose of 3% topical minoxidil in male pattern baldness
- 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials
- Case 2-2022: An Adolescent Male in Cardiac Arrest 3 Days After Liver Transplantation for End-Stage Liver Disease
- The synthesis of (−)-4-methyl-8-chloro-trans-1,2,3,4,4a,5,6,10b-octahydrobenzo-[f]-quinolin-3-one-[3-14C] (LY300502-14C]) via a circuitous route
- 54022 Pooled Safety Assessments from the Multinational Phase 3 THRIVE-AA1 and THRIVE-AA2 Trials of Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata
- Generation of human-induced pluripotent stem cell-derived adherent 3-dimensional skin hair-follicle organoids
- Comment on “Low dose oral minoxidil for treating alopecia: A 3-year North American retrospective case series”: Adding further evidence about side effects
- Crystal Structure and Synthesis of 17α-Hexanoyloxy-16β-methylpregna-4,6-diene-3,20-dione
- NTP Toxicology and Carcinogenesis Studies of C.I. Acid Orange 3 (CAS No. 6373-74-6) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
- 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
- 42005 Sustained scalp, eyebrow, and eyelash hair regrowth with ritlecitinib through Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
- The neurosteroid metabolite of progesterone, 3α‐OH‐dihydroprogesterone (3α‐OH‐DHP), is required for attenuated baroreflex mediated sympathoexcitation in pregnancy
- Impact of Disease History on the Efficacy of Ritlecitinib in Patients With Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
- Katsuwonus pelamis heart hydrolysates promote hair growth in 3-dimensional human hair follicle organoids and in mice
- iPrimer-seq: A Streamlined and Cost-Effective Early-Barcoding 3'-End Rna-Seq Method for Transcriptome Profiling from Limiting Cell Inputs
- Tuning Scaffold Properties of New 1,4-Substituted Pyrrolo[3,2-c]quinoline Derivatives Endowed with Anticancer Potential, New Biological and In Silico Insights
- Updated Integrated Efficacy Analysis of Ritlecitinib Up to 3 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
- Evaluación pronóstica de la escala delta-sofa a los 3 y 5 días del ingreso en uci asociado al saps 3 y creación de un modelo objetivo para la adecuación ética del esfuerzo terapéutico
- 49690 Long-term efficacy of baricitinib in alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2